Katharina Hintelmann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Katharina Hintelmann has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
David Krug
Klinik für Strahlentherapie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Deutschland
3 shared publications- Anna Jaeger
Department of Gynecology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
1 shared publication - Annika Tamenang
Department of Tumor Biology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246 Hamburg, Germany
1 shared publication - Barbara Schmalfeldt
Department of Gynecology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246 Hamburg, Germany
1 shared publication - Charlotte Schwartz
Department of Tumor Biology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246 Hamburg, Germany
1 shared publication Cordula Petersen
Department of Radiotherapy and Radiation Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
1 shared publication
Latest Publications
- Open Access
- 27 May 2026
- Published by Springer Nature in Strahlentherapie und Onkologie
- Vol. 202 (6) , 581-584
Gender disparities in historical context, workforce structure, and decision-making
- 27 May 2026
- Published by Springer Nature in Strahlentherapie und Onkologie
- Vol. 202 (6) , 581-584
Open AccessGender disparities in historical context, workforce structure, and decision-making
- Open Access
Circulating microRNA Profiles as Diagnostic Tools for High-Grade Cervical Lesions and HPV Genotype Stratification
Persistent high-risk human papillomavirus (hr-HPV) infection drives cervical carcinogenesis, yet improved molecular biomarkers are needed to define high-risk groups. Circulating microRNAs (miRNAs), stable in blood and involved in carcinogenic pathways, represent promising liquid biopsy biomarkers. This study assessed five miRNAs for distinguishing high-grade squamous cell intraepithelial lesions (HSILs) and cervical cancer from healthy controls and for HPV stratification. Circulating miRNAs were quantified in blood samples from 80 women (38 HSIL, 10 cervical cancer, and 32 controls). Relative expression by disease and HPV status was measured by RT-qPCR and normalized to miRNA-23a. Diagnostic performance of single and combined miRNAs was evaluated by logistic regression and ROC curve analysis. Three circulating miRNAs (miR-21, miR-205, and miR-218) were found to be significantly differentially dysregulated in the patient cohorts. A combination of the three markers showed the best diagnostic value for HSIL (AUC of 0.81, sensitivity of 79%, and specificity of 71%) and cancer (AUC of 0.81, sensitivity of 90%, and specificity of 65%). Whereas miR-205 was significantly associated with HPV16/18 in HSIL patients, the combined model had the highest diagnostic performance for multiple HPV infections. Circulating miRNA signatures show promise as liquid biopsy biomarkers for detecting cervical dysplasia and stratifying for HPV status in HSIL, warranting validation in larger prospective studies.
Open AccessCirculating microRNA Profiles as Diagnostic Tools for High-Grade Cervical Lesions and HPV Genotype Stratification
Persistent high-risk human papillomavirus (hr-HPV) infection drives cervical carcinogenesis, yet improved molecular biomarkers are needed to define high-risk groups. Circulating microRNAs (miRNAs), stable in blood and involved in carcinogenic pathways, represent promising liquid biopsy biomarkers. This study assessed five miRNAs for distinguishing high-grade squamous cell intraepithelial lesions (HSILs) and cervical cancer from healthy controls and for HPV stratification. Circulating miRNAs were quantified in blood samples from 80 women (38 HSIL, 10 cervical cancer, and 32 controls). Relative expression by disease and HPV status was measured by RT-qPCR and normalized to miRNA-23a. Diagnostic performance of single and combined miRNAs was evaluated by logistic regression and ROC curve analysis. Three circulating miRNAs (miR-21, miR-205, and miR-218) were found to be significantly differentially dysregulated in the patient cohorts. A combination of the three markers showed the best diagnostic value for HSIL (AUC of 0.81, sensitivity of 79%, and specificity of 71%) and cancer (AUC of 0.81, sensitivity of 90%, and specificity of 65%). Whereas miR-205 was significantly associated with HPV16/18 in HSIL patients, the combined model had the highest diagnostic performance for multiple HPV infections. Circulating miRNA signatures show promise as liquid biopsy biomarkers for detecting cervical dysplasia and stratifying for HPV status in HSIL, warranting validation in larger prospective studies.
- 15 April 2026
- Published by Springer Nature in Die Gynäkologie
- Vol. 59 (5) , 300-305
Update Strahlentherapie beim Mammakarzinom
- 15 April 2026
- Published by Springer Nature in Die Gynäkologie
- Vol. 59 (5) , 300-305
Update Strahlentherapie beim Mammakarzinom
- Open Access
- 7 March 2025
- Published by Springer Nature in Strahlentherapie und Onkologie
- Vol. 201 (6) , 606-615
Radiotherapy in breast cancer brain metastases: the impact of time interval and disease dynamics when breast cancer seeds to the brain
Purpose: The initial brain metastasis velocity (iBMV) is a prognostic metric introduced for patients receiving stereotactic radiosurgery (SRS) for brain metastases (BM), reflecting intracranial disease dynamics. This study aimed to assess the applicability of iBMV in a mixed cohort of breast cancer brain metastases (BCBM) patients treated with SRS/fractionated stereotactic radiotherapy (FSRT) and whole-brain radiotherapy (WBRT). Considering disease dynamics, we analyzed the role of biological subtypes in determining the time interval between initial diagnosis and the occurrence of BM. Methods: We conducted a retrospective, single center cohort study of 126 BCBM patients who received radiotherapy to the brain (SRS/FSRT and WBRT) between 01/2013 and 12/2020. Statistical endpoints included iBMV, time interval between initial diagnosis and the occurrence of BM analyzed per biological subtype, and overall survival (OS). Results: Median iBMV was 0.48 BM/year. The iBMV independently predicted for mortality in the multivariate model after accounting for WBRT (hazard ratio [HR] = 1.21; 95% confidence interval [CI] 1.04–1.41; p = 0.012). The biologic subtype significantly influenced the time interval between initial diagnosis of breast cancer and occurrence of BM. In a multivariate model, the Karnofsky performance status and HER2 status were strongest predictors of overall survival (HR = 2.60; 95% CI 1.60–4.22; p < 0.001 and HR = 2.26; 95% CI 1.34–3.84; p = 0.002, respectively). Conclusion: iBMV correlates with overall survival, regardless of whether WBRT was used as part of local treatment. The biological subtype has a profound impact on prognosis and kinetics of BCBM.
- 7 March 2025
- Published by Springer Nature in Strahlentherapie und Onkologie
- Vol. 201 (6) , 606-615
Open AccessRadiotherapy in breast cancer brain metastases: the impact of time interval and disease dynamics when breast cancer seeds to the brain
Purpose: The initial brain metastasis velocity (iBMV) is a prognostic metric introduced for patients receiving stereotactic radiosurgery (SRS) for brain metastases (BM), reflecting intracranial disease dynamics. This study aimed to assess the applicability of iBMV in a mixed cohort of breast cancer brain metastases (BCBM) patients treated with SRS/fractionated stereotactic radiotherapy (FSRT) and whole-brain radiotherapy (WBRT). Considering disease dynamics, we analyzed the role of biological subtypes in determining the time interval between initial diagnosis and the occurrence of BM. Methods: We conducted a retrospective, single center cohort study of 126 BCBM patients who received radiotherapy to the brain (SRS/FSRT and WBRT) between 01/2013 and 12/2020. Statistical endpoints included iBMV, time interval between initial diagnosis and the occurrence of BM analyzed per biological subtype, and overall survival (OS). Results: Median iBMV was 0.48 BM/year. The iBMV independently predicted for mortality in the multivariate model after accounting for WBRT (hazard ratio [HR] = 1.21; 95% confidence interval [CI] 1.04–1.41; p = 0.012). The biologic subtype significantly influenced the time interval between initial diagnosis of breast cancer and occurrence of BM. In a multivariate model, the Karnofsky performance status and HER2 status were strongest predictors of overall survival (HR = 2.60; 95% CI 1.60–4.22; p < 0.001 and HR = 2.26; 95% CI 1.34–3.84; p = 0.002, respectively). Conclusion: iBMV correlates with overall survival, regardless of whether WBRT was used as part of local treatment. The biological subtype has a profound impact on prognosis and kinetics of BCBM.
- Open Access
- 17 December 2024
- Published by Springer Nature in Strahlentherapie und Onkologie
- Vol. 201 (3) , 343-345
Olaparib bei biochemischem Rezidiv des High-risk-Prostatakarzinoms nach Prostatektomie
- 17 December 2024
- Published by Springer Nature in Strahlentherapie und Onkologie
- Vol. 201 (3) , 343-345
Open AccessOlaparib bei biochemischem Rezidiv des High-risk-Prostatakarzinoms nach Prostatektomie
- 6 December 2024
- Published by Springer Nature in Die Onkologie
- Vol. 31 (3) , 276-281
Update Teilbrustbestrahlung
- 6 December 2024
- Published by Springer Nature in Die Onkologie
- Vol. 31 (3) , 276-281
Update Teilbrustbestrahlung
- Open Access
- 12 October 2023
- Published by Springer Nature in Strahlentherapie und Onkologie
- Vol. 199 (12) , 1258-1261
Das BRCA-like-Mammakarzinom profitiert von Cisplatin plus Veliparib; Ergebnisse der S1416-Phase-II-Studie
- 12 October 2023
- Published by Springer Nature in Strahlentherapie und Onkologie
- Vol. 199 (12) , 1258-1261
Open AccessDas BRCA-like-Mammakarzinom profitiert von Cisplatin plus Veliparib; Ergebnisse der S1416-Phase-II-Studie
- Open Access
Radiotherapeutic Strategies to Overcome Resistance of Breast Cancer Brain Metastases by Considering Immunogenic Aspects of Cancer Stem Cells
Breast cancer is the most diagnosed cancer in women, and symptomatic brain metastases (BCBMs) occur in 15–20% of metastatic breast cancer cases. Despite technological advances in radiation therapy (RT), the prognosis of patients is limited. This has been attributed to radioresistant breast cancer stem cells (BCSCs), among other factors. The aim of this review article is to summarize the evidence of cancer-stem-cell-mediated radioresistance in brain metastases of breast cancer from radiobiologic and radiation oncologic perspectives to allow for the better interpretability of preclinical and clinical evidence and to facilitate its translation into new therapeutic strategies. To this end, the etiology of brain metastasis in breast cancer, its radiotherapeutic treatment options, resistance mechanisms in BCSCs, and effects of molecularly targeted therapies in combination with radiotherapy involving immune checkpoint inhibitors are described and classified. This is considered in the context of the central nervous system (CNS) as a particular metastatic niche involving the blood–brain barrier and the CNS immune system. The compilation of this existing knowledge serves to identify possible synergistic effects between systemic molecularly targeted therapies and ionizing radiation (IR) by considering both BCSCs’ relevant resistance mechanisms and effects on normal tissue of the CNS.
Open AccessRadiotherapeutic Strategies to Overcome Resistance of Breast Cancer Brain Metastases by Considering Immunogenic Aspects of Cancer Stem Cells
Breast cancer is the most diagnosed cancer in women, and symptomatic brain metastases (BCBMs) occur in 15–20% of metastatic breast cancer cases. Despite technological advances in radiation therapy (RT), the prognosis of patients is limited. This has been attributed to radioresistant breast cancer stem cells (BCSCs), among other factors. The aim of this review article is to summarize the evidence of cancer-stem-cell-mediated radioresistance in brain metastases of breast cancer from radiobiologic and radiation oncologic perspectives to allow for the better interpretability of preclinical and clinical evidence and to facilitate its translation into new therapeutic strategies. To this end, the etiology of brain metastasis in breast cancer, its radiotherapeutic treatment options, resistance mechanisms in BCSCs, and effects of molecularly targeted therapies in combination with radiotherapy involving immune checkpoint inhibitors are described and classified. This is considered in the context of the central nervous system (CNS) as a particular metastatic niche involving the blood–brain barrier and the CNS immune system. The compilation of this existing knowledge serves to identify possible synergistic effects between systemic molecularly targeted therapies and ionizing radiation (IR) by considering both BCSCs’ relevant resistance mechanisms and effects on normal tissue of the CNS.